EU regulators set to pause subsidy probe into ADNOC's Covestro deal, source says

EU antitrust regulators are set to pause their investigation into Abu Dhabi state oil giant ADNOC's 14.7-billion-euro acquisition of German chemicals company Covestro. This temporary halt aims to allow the European Commission more time to gather information, following constructive talks with ADNOC on potential remedies. The probe had focused on concerns regarding potential UAE subsidies, such as an unlimited guarantee, for the significant deal, which is ADNOC's largest acquisition and one of the biggest foreign takeovers of an EU company by a Gulf state. A decision is due by December 2.

Analysis

The European Commission's antitrust investigation into Abu Dhabi National Oil Company's (ADNOC) proposed €14.7 billion acquisition of Covestro is set to be temporarily paused. This procedural halt is intended to provide regulators with additional time to gather information, a development that follows what were described as "constructive talks" between ADNOC and the EU competition enforcer regarding potential remedies. The core of the EU's probe, initiated in July, centers on concerns over potential distorting subsidies from the United Arab Emirates, including an unlimited guarantee and a committed capital increase for the deal. While the pause introduces a delay, the concurrent discussion of remedies suggests a pathway to approval may be forming, rather than an outright blockage of what stands as ADNOC's largest-ever acquisition. The final decision deadline remains set for December 2, making the nature of any agreed-upon remedies the critical factor for the deal's ultimate success.

Key Decisions for Investors

• Investors in Covestro should interpret the pause not as a negative signal, but as a procedural delay that, when coupled with constructive talks on remedies, may slightly increase the probability of the deal's eventual closure.
• Merger arbitrage funds should adjust their timelines to account for the extended regulatory review, while closely monitoring for disclosures on the specific remedies being offered, as these will determine the final risk profile and timeline before the December 2 deadline.
• The focus on UAE subsidies signals heightened EU regulatory scrutiny for state-backed foreign takeovers; investors should factor this heightened regulatory risk into valuations for any European M&A targets involving non-EU state-owned enterprises.